<DOC>
	<DOCNO>NCT00589056</DOCNO>
	<brief_summary>RATIONALE : Nelfinavir may stop growth tumor cell block enzymes need cell growth . Radiation therapy use high energy x-ray kill tumor cell . Nelfinavir may make tumor cell sensitive radiation therapy . Drugs use chemotherapy , cisplatin etoposide , work different way stop growth tumor cell , either kill cell stop divide . Giving nelfinavir together radiation therapy , cisplatin , etoposide may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose nelfinavir give together radiation therapy , cisplatin , etoposide see well work treat patient stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Nelfinavir , Radiation Therapy , Cisplatin , Etoposide Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine dose-limiting toxicity , maximum tolerate dose , recommend phase II dose nelfinavir mesylate administer combination concurrent thoracic radiotherapy , cisplatin , etoposide patient unresectable locally advanced non-small cell lung cancer . Secondary - To determine tumor response 3 month completion treatment measure RECIST criterion . - To assess inhibition p-Akt primary tumor pathologic lymph node peripheral blood lymphocytes 5-10 day treatment nelfinavir mesylate . - To determine median overall survival ( OS ) patient treat regimen . - To compare observed median OS patient historical median OS 17 month . OUTLINE : This phase I , dose-escalation study nelfinavir mesylate follow phase II study . - Phase I : Patients receive oral nelfinavir mesylate twice daily begin 1-2 week initiation chemoradiotherapy continue completion radiotherapy . Patients undergo thoracic radiotherapy daily 5 day week 7-8 week . Patients also receive cisplatin IV day 1 , 8 , 29 , 36 etoposide IV day 1-5 29-33 . After completion chemoradiotherapy , patient receive two additional course cisplatin etoposide . - Phase II : Patients receive nelfinavir mesylate maximum tolerate dose determined phase I concurrent chemoradiotherapy phase I . Patients undergo blood sample collection periodically correlative laboratory study . Patients treat phase II portion study primary tumor pathologic lymph node easily accessible core biopsy mediastinoscopy also undergo tumor tissue biopsy . Blood tumor tissue sample analyze expression molecular marker ( total Akt p-Akt ) immunohistochemistry . The molecular marker correlate treatment response . After completion study treatment , patient follow 3 , 6 , 12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer Locally advance ( stage III ) disease Unresectable disease Candidate concurrent definitive chemotherapy thoracic radiotherapy , determine treat physician No malignant pleural effusion PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN FEV_1 &gt; 600 cc Not pregnant nursing Negative pregnancy test No weight loss &gt; 10 % within past 6 month No know HIV disease PRIOR CONCURRENT THERAPY : No prior thoracic radiotherapy No prior HIV protease inhibitor More 5 year since prior chemotherapy At least 3 week since prior exploratory thoracotomy No concurrent medication would preclude nelfinavir administration , include follow : Amiodarone Quinidine Rifampin Dihydroergotamine Ergonovine Ergotamine Methylergonovine Hypericum perforatum ( St. John 's wort ) Lovastatin Simvastatin Pimozide Midazolam Triazolam</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>